N-RAP Inhibitors
Chemical inhibitors of N-RAP target various aspects of muscle cell structure and function, which is central to the protein's role in myofibrillogenesis. Blebbistatin operates by inhibiting myosin II, a motor protein that interacts with N-RAP during the assembly of myofibrils. By impeding myosin II's function, Blebbistatin can disrupt the proper organization and assembly of myofibrils, directly inhibiting N-RAP's role in this essential cellular process. Similarly, ML-7 targets the myosin light chain kinase (MLCK), which is involved in the regulation of muscle contraction and myofibril structure. ML-7's inhibition of MLCK leads to a decrease in myofibril tension and organization, an environment in which N-RAP cannot function optimally. Y-27632 and H-1152, both inhibitors of Rho-associated protein kinase (ROCK), impair the actin cytoskeleton organization. Since N-RAP's function is closely tied to actin dynamics within muscle cells, the inhibition of ROCK results in an environment that is unsuitable for N-RAP's role in myofibril assembly.
Further targeting actin dynamics, Latrunculin B and CK-636 disrupt the polymerization and nucleation of actin filaments, respectively. As N-RAP is intricately involved in actin filament organization, the presence of these inhibitors hampers the formation of the actin cytoskeleton, thus inhibiting N-RAP's function. SMIFH2, which inhibits formin homology 2 domain proteins, further disrupts actin filament assembly, a process essential for N-RAP's activity in organizing myofibrils. Other chemicals such as Gö 6983 and BMS-5 inhibit protein kinase C and LIM kinase, respectively, both of which are involved in signaling pathways that govern myofibrillogenesis. By disrupting these pathways, these inhibitors create conditions that are unfavorable for the activity of N-RAP. Wortmannin, by inhibiting phosphoinositide 3-kinase, can disrupt the organization of the actin cytoskeleton, leading to the functional inhibition of N-RAP. Marimastat, targeting matrix metalloproteinases, affects the extracellular matrix remodeling, indirectly inhibiting N-RAP by altering the cellular adhesion and signaling environment. Lastly, Concanamycin A disrupts cellular pH gradients by inhibiting the vacuolar type H+-ATPase, affecting cytoskeletal dynamics and consequently inhibiting N-RAP's role in muscle cell structure.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Blebbistatin inhibits myosin II, which N-RAP interacts with during myofibril assembly. By inhibiting myosin II, Blebbistatin can disrupt the proper assembly of myofibrils, leading to functional inhibition of N-RAP. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK), which plays a role in muscle contraction and structure. Inhibition of MLCK can lead to a decrease in myofibril organization and tension, which can inhibit N-RAP's role in myofibrillogenesis. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a Rho-associated protein kinase (ROCK) inhibitor. Since N-RAP is involved in actin dynamics and myofibril assembly, inhibition of ROCK can impair actin organization, thereby inhibiting N-RAP's function in muscle cells. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö 6983 is a protein kinase C (PKC) inhibitor. PKC is involved in myofibrillogenesis and by inhibiting PKC, Gö 6983 can disrupt signaling pathways important for N-RAP's role in myofibril organization. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor. PI3K is involved in multiple cellular processes, including actin cytoskeleton organization. Inhibition of PI3K can disrupt actin dynamics, leading to inhibition of N-RAP's function. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Latrunculin B binds to actin monomers and prevents their polymerization. N-RAP is involved in actin filament organization, so latrunculin B can inhibit N-RAP's function by disrupting actin filament formation. | ||||||
SMIFH2 | 340316-62-3 | sc-507273 | 5 mg | $140.00 | ||
SMIFH2 is an inhibitor of formin homology 2 (FH2) domain proteins, which are involved in actin nucleation and elongation. By inhibiting FH2 domain proteins, SMIFH2 can disrupt actin filament assembly, thus inhibiting N-RAP's function in myofibrillogenesis. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloproteinase (MMP) inhibitor. MMPs are involved in extracellular matrix remodeling, which is important for muscle tissue organization. Inhibition of MMPs can lead to altered cellular adhesion and signaling, indirectly inhibiting N-RAP's role in muscle cell organization. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A is a vacuolar type H+-ATPase inhibitor which can disrupt cellular pH gradients. Since N-RAP is involved in cytoskeletal organization, disruption of pH gradients can impair cytoskeletal dynamics and thus functionally inhibit N-RAP. | ||||||
H-1152 dihydrochloride | 451462-58-1 | sc-203592 sc-203592A | 1 mg 5 mg | $104.00 $364.00 | 7 | |
H-1152 is a more potent ROCK inhibitor compared to Y-27632. By inhibiting ROCK, H-1152 can lead to reduced stress fiber formation and altered myofibril assembly, thereby inhibiting N-RAP's ability to maintain muscle cell structure. | ||||||